These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29573098)

  • 1. Rosiglitazone lowers resting and blood pressure response to exercise in men with type 2 diabetes: A 1-year randomized study.
    Piché ME; Laberge AS; Brassard P; Arsenault BJ; Bertrand OF; Després JP; Costerousse O; Poirier P
    Diabetes Obes Metab; 2018 Jul; 20(7):1740-1750. PubMed ID: 29573098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of PPARγ agonist on aerobic exercise capacity in relation to body fat distribution in men with type 2 diabetes mellitus and coronary artery disease: a 1-yr randomized study.
    Bastien M; Poirier P; Brassard P; Arsenault BJ; Bertrand OF; Després JP; Costerousse O; Piché ME
    Am J Physiol Endocrinol Metab; 2019 Jul; 317(1):E65-E73. PubMed ID: 30964707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
    Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
    Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients.
    Negro R; Mangieri T; Dazzi D; Pezzarossa A; Hassan H
    Diabetes Res Clin Pract; 2005 Oct; 70(1):20-5. PubMed ID: 16126119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exercise-induced exaggerated blood pressure response in men with the metabolic syndrome: the role of the autonomous nervous system.
    Gaudreault V; Després JP; Rhéaume C; Bergeron J; Alméras N; Tremblay A; Poirier P
    Blood Press Monit; 2013 Oct; 18(5):252-8. PubMed ID: 23903294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
    Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
    Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial.
    Stirban AO; Andjelkovic M; Heise T; Nosek L; Fischer A; Gastaldelli A; Herz M
    Diabetes Obes Metab; 2016 Jul; 18(7):711-5. PubMed ID: 26663152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty.
    Wang G; Wei J; Guan Y; Jin N; Mao J; Wang X
    Metabolism; 2005 May; 54(5):590-7. PubMed ID: 15877288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
    Balasubramanian R; Gerrard J; Dalla Man C; Firbank MJ; Lane A; English PT; Cobelli C; Taylor R
    Diabet Med; 2010 Feb; 27(2):150-6. PubMed ID: 20546257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic metabolic markers and myocardial glucose uptake in type 2 diabetic and coronary artery disease patients treated for 16 weeks with rosiglitazone, a PPARγ agonist.
    Badeau RM; Honka MJ; Lautamäki R; Stewart M; Kangas AJ; Soininen P; Ala-Korpela M; Nuutila P
    Ann Med; 2014 Feb; 46(1):18-23. PubMed ID: 24266715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase.
    Sarafidis PA; Lasaridis AN; Nilsson PM; Pagkalos EM; Hitoglou-Makedou AD; Pliakos CI; Kazakos KA; Yovos JG; Zebekakis PE; Tziolas IM; Tourkantonis AN
    J Hypertens; 2004 Sep; 22(9):1769-77. PubMed ID: 15311106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D supplementation improves SIRT1, Irisin, and glucose indices in overweight or obese type 2 diabetic patients: a double-blind randomized placebo-controlled clinical trial.
    Safarpour P; Daneshi-Maskooni M; Vafa M; Nourbakhsh M; Janani L; Maddah M; Amiri FS; Mohammadi F; Sadeghi H
    BMC Fam Pract; 2020 Feb; 21(1):26. PubMed ID: 32033527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosiglitazone, a peroxisome proliferator-activated receptor γ stimulant, abrogates diabetes-evoked hypertension by rectifying abnormalities in vascular reactivity.
    El-Bassossy HM; Abo-Warda SM; Fahmy A
    Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):643-9. PubMed ID: 22594672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes.
    Erdmann E; Califf R; Gerstein HC; Malmberg K; Ruilope L; Schwartz GG; Wedel H; Volz D; Ditmarsch M; Svensson A; Bengus M
    Am Heart J; 2015 Jul; 170(1):117-22. PubMed ID: 26093872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.
    Buse JB; Rubin CJ; Frederich R; Viraswami-Appanna K; Lin KC; Montoro R; Shockey G; Davidson JA
    Clin Ther; 2005 Aug; 27(8):1181-95. PubMed ID: 16199244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes.
    Hällsten K; Virtanen KA; Lönnqvist F; Sipilä H; Oksanen A; Viljanen T; Rönnemaa T; Viikari J; Knuuti J; Nuutila P
    Diabetes; 2002 Dec; 51(12):3479-85. PubMed ID: 12453903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus.
    Kim HJ; Kim SK; Shim WS; Lee JH; Hur KY; Kang ES; Ahn CW; Lim SK; Lee HC; Cha BS
    Diabetes Res Clin Pract; 2008 Jul; 81(1):42-9. PubMed ID: 18394743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosiglitazone Elicits an Adiponectin-Mediated Insulin-Sensitizing Action at the Adipose Tissue-Liver Axis in Otsuka Long-Evans Tokushima Fatty Rats.
    Li J; Xue YM; Zhu B; Pan YH; Zhang Y; Wang C; Li Y
    J Diabetes Res; 2018; 2018():4627842. PubMed ID: 30225267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone.
    Hällsten K; Virtanen KA; Lönnqvist F; Janatuinen T; Turiceanu M; Rönnemaa T; Viikari J; Lehtimäki T; Knuuti J; Nuutila P
    Diabet Med; 2004 Dec; 21(12):1280-7. PubMed ID: 15569129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.